BTG pulmonary embolism treatment granted FDA clearance in US

23rd May 2014 07:57

BTG has been granted clearance for its EkoSonic Endovascular System treatment of pulmonary embolism (PE) by the US Food and Drug Administration (FDA). The minimally invasive treatment carries out the ultrasound-facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, for the treatment of PE.Professor Samuel Goldhaber of the Thrombosis Research Group at Brigham and Woman's Hospital, said: "The Ekos clinical data established that patients stricken with a life-threatening pulmonary embolism can be successfully and safely treated with the EkoSonic system. This is the first FDA cleared treatment option for PE since the approval of the drug, tPA, in 1990.""Interventional radiologists, cardiologists, cardiothoracic and vascular surgeons at leading institutions around the world use our system to provide faster, safer and more complete dissolution of thrombus," added Matt Stupfel, the General Manager of Ekos. NR